GARDEN (Global Hematological Rare Diseases Alliance)/LinkedIn
May 23, 2026, 14:42
How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
GARDEN (Global Hematological Rare Diseases Alliance) shared a post on LinkedIn:
“How should evidence be interpreted in modern hemophilia care?
In this new contribution from the GARDEN editorial series, Prof. Cedric Hermans explores the methodological debate behind international hemophilia guidelines, examining the balance between randomized clinical trials, real-world evidence, and patient-centered decision-making.
A critical reflection on how evidence shapes clinical practice, access to care, and the future of hemophilia management.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026